Intellia Therapeutics Inc (NASDAQ:NTLA) has been given a $33.00 target price by analysts at Jefferies Group in a report issued on Wednesday. The firm presently has a a “buy” rating on the stock. Jefferies Group’s price objective indicates a potential upside of 100.12% from the stock’s current price.

Several other equities analysts also recently commented on the stock. Janney Montgomery Scott initiated coverage on shares of Intellia Therapeutics in a research report on Wednesday, September 28th. They set a “buy” rating and a $29.00 target price on the stock. Zacks Investment Research upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, September 22nd. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Intellia Therapeutics in a report on Tuesday, August 23rd. Finally, Leerink Swann upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a report on Friday, August 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $34.20.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Shares of Intellia Therapeutics (NASDAQ:NTLA) traded up 7.5798% during trading on Wednesday, hitting $17.7399. The stock had a trading volume of 1,255,780 shares. Intellia Therapeutics has a 12-month low of $16.07 and a 12-month high of $30.40. The stock’s 50 day moving average is $19.78 and its 200-day moving average is $22.00. The company’s market cap is $638.55 million.

Several large investors have recently added to or reduced their stakes in NTLA. BlackRock Advisors LLC bought a new stake in Intellia Therapeutics during the second quarter valued at $13,146,000. BlackRock Institutional Trust Company N.A. bought a new stake in Intellia Therapeutics during the second quarter valued at $1,236,000. BlackRock Fund Advisors bought a new stake in Intellia Therapeutics during the second quarter valued at $3,496,000. BlackRock Investment Management LLC bought a new stake in Intellia Therapeutics during the second quarter valued at $553,000. Finally, Vanguard Group Inc. bought a new stake in Intellia Therapeutics during the second quarter valued at $8,894,000.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

5 Day Chart for NASDAQ:NTLA

Receive News & Stock Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related stocks with our FREE daily email newsletter.